Evidence map›Paper›PMID 37241602›Full record

ReviewMicromachines2023

Engineered Vasculature for Cancer Research and Regenerative Medicine.

Huu Tuan Nguyen, Arne Peirsman, Zuzana Tirpakova, Kalpana Mandal, Florian Vanlauwe, Surjendu Maity, Satoru Kawakita, Danial Khorsandi, Rondinelli Herculano, Christian Umemura and 11 more

Open access · goldAbstract readReview
In one paragraph

Review in Micromachines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 5 countries.

Huu Tuan NguyenTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Arne PeirsmanTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0000-0002-6519-8367
Zuzana TirpakovaTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Kalpana MandalTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Florian VanlauwePlastic, Reconstructive and Aesthetic Surgery, Ghent University Hospital, 9000 Ghent, Belgium.
Surjendu MaityTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0000-0003-0190-248X
Satoru KawakitaTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Danial KhorsandiTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Rondinelli HerculanoTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Christian UmemuraTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Can YilgorTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0009-0000-9214-4324
Remy BellTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0000-0002-4737-6553
Adrian HansonTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Shaopei LiTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Himansu Sekhar NandaTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Yangzhi ZhuTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Alireza Hassani NajafabadiTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Vadim JucaudTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0000-0003-0385-2623
Natan BarrosTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Mehmet Remzi DokmeciTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.ORCID 0000-0002-2692-1524
Terasaki Foundation · USGhent University Hospital · BEIndian Institute of Information Technology Design and Manufacturing Jabalpur · INUniversity of Veterinary Medicine in Košice · SK

Funding

Drug eluting injectable biomaterials for next generation chemoembolizationR01CA257558 · NCI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2021 to 2025
$3.2M
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.UH3TR003148 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASHAMMAKHI, NUREDDIN, MAIDMENT, NIGEL T · 2022 to 2024
$2.4M
3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
Oxygen generating bioinks for 3D printed bone implantsR01AR074234 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON · 2018 to 2022
$1.9M
Stem cell-loaded microgels to treat discogenic low back painR34NS126032 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI SHEYN, DMITRIY · 2021 to 2021
$1.7M
Research Supplements to Promote DiversityR01GM126571 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, YE, JING YONG · 2018 to 2021
$1.3M
NCATS NIH HHS UH3 TR003148NCI NIH HHS R01 CA257558NIAMS NIH HHS R01 AR073135NIAMS NIH HHS R01 AR074234NIGMS NIH HHS R01 GM126571NIH HHS R01AR073135NIH HHS R01AR074234NIH HHS R01GM126571NIH HHS R34NS126032NIH HHS UH3TR003148NINDS NIH HHS R34 NS126032
6 · The paper itself

Abstract

Engineered human tissues created by three-dimensional cell culture of human cells in a hydrogel are becoming emerging model systems for cancer drug discovery and regenerative medicine. Complex functional engineered tissues can also assist in the regeneration, repair, or replacement of human tissues. However, one of the main hurdles for tissue engineering, three-dimensional cell culture, and regenerative medicine is the capability of delivering nutrients and oxygen to cells through the vasculatures. Several studies have investigated different strategies to create a functional vascular system in engineered tissues and organ-on-a-chips. Engineered vasculatures have been used for the studies of angiogenesis, vasculogenesis, as well as drug and cell transports across the endothelium. Moreover, vascular engineering allows the creation of large functional vascular conduits for regenerative medicine purposes. However, there are still many challenges in the creation of vascularized tissue constructs and their biological applications. This review will summarize the latest efforts to create vasculatures and vascularized tissues for cancer research and regenerative medicine.

Indexed as

cancerengineered vasculaturemicrofluidicsorgan-on-a-chipregenerative medicine

Identifiers

PMID37241602
PMCPMC10221678
OpenAlexW4367678605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.